Innocutis introduces Sitavig tabs

CHARLESTON, S.C. — Innocutis on Monday announced the introduction of Sitavig (acyclovir) 50-mg buccal tablet into North American markets. The tablet, developed by BioAlliance and licensed to Innocutis, is indicated for relief of herpes labialis or cold sores.



The tablet sticks to the gum above the incisor tooth on the side of the lip infected with a cold sore, the company said. The tablet is tasteless, odorless and dissolves to provide a continous release of medicine.



"We are very excited to bring Sitavig to the North American markets," said Charles Jenkins, VP marketing for Innocutis. "Up to 90% of Americans have been exposed to HSV by the time they are 50 years old, but there hasn't been a real breakthrough product to address this problem in many years. Sitavig is revolutionary because unlike systemic drugs and topical prescription creams, Sitavig requires application to the gum only once per episode. It is available by prescription only at local retail pharmacies."